WO2008026075A3 - Treatment of intracellular bacterial infections with a protein kinase inhibitor or an as160 polypeptide activator - Google Patents
Treatment of intracellular bacterial infections with a protein kinase inhibitor or an as160 polypeptide activator Download PDFInfo
- Publication number
- WO2008026075A3 WO2008026075A3 PCT/IB2007/003553 IB2007003553W WO2008026075A3 WO 2008026075 A3 WO2008026075 A3 WO 2008026075A3 IB 2007003553 W IB2007003553 W IB 2007003553W WO 2008026075 A3 WO2008026075 A3 WO 2008026075A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein kinase
- kinase inhibitor
- bacterial infections
- treatment
- intracellular bacterial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Products for treating intracellular bacterial infections comprising a protein kinase inhibitor and/or an activator of AS160 polypeptide-. The protein kinase inhibitor may be a H-89 derivative.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0617222.5 | 2006-08-31 | ||
GBGB0617222.5A GB0617222D0 (en) | 2006-08-31 | 2006-08-31 | Antibiotics |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008026075A2 WO2008026075A2 (en) | 2008-03-06 |
WO2008026075A3 true WO2008026075A3 (en) | 2009-01-22 |
Family
ID=37137160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/003553 WO2008026075A2 (en) | 2006-08-31 | 2007-08-31 | Treatment of intracellular bacterial infections with a protein kinase inhibitor or an as160 polypeptide activator |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0617222D0 (en) |
WO (1) | WO2008026075A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103173529B (en) | 2011-12-23 | 2015-04-29 | 上海吉凯基因化学技术有限公司 | Associated use of human NLK (Neuroleukin) gene and associated medicines |
EP3027654B1 (en) * | 2013-07-30 | 2019-09-25 | Blueprint Medicines Corporation | Pik3c2g fusions |
WO2019165067A1 (en) | 2018-02-21 | 2019-08-29 | Bristol-Myers Squibb Company | Camk2d antisense oligonucleotides and uses thereof |
IL296252A (en) * | 2020-03-06 | 2022-11-01 | Endolytix Tech Inc | Compositions and methods for the treatment of intracellular bacterial infections |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5081246A (en) * | 1988-12-26 | 1992-01-14 | Hiroyoshi Hidaka | Compound having vessel smooth muscle relaxation activity |
EP0956865A1 (en) * | 1996-08-12 | 1999-11-17 | Yoshitomi Pharmaceutical Industries, Ltd. | MEDICINES COMPRISING Rho KINASE INHIBITOR |
WO2001091754A1 (en) * | 2000-05-30 | 2001-12-06 | Peptor Ltd. | Protein kinase inhibitors |
US20030180830A1 (en) * | 2002-02-14 | 2003-09-25 | Pyro Pharmaceuticals, Inc. | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway |
WO2004087943A1 (en) * | 2003-03-29 | 2004-10-14 | Astrazeneca Ab | Method |
US20050164323A1 (en) * | 2003-12-24 | 2005-07-28 | Wyeth | Methods of treating asthma |
-
2006
- 2006-08-31 GB GBGB0617222.5A patent/GB0617222D0/en not_active Ceased
-
2007
- 2007-08-31 WO PCT/IB2007/003553 patent/WO2008026075A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5081246A (en) * | 1988-12-26 | 1992-01-14 | Hiroyoshi Hidaka | Compound having vessel smooth muscle relaxation activity |
EP0956865A1 (en) * | 1996-08-12 | 1999-11-17 | Yoshitomi Pharmaceutical Industries, Ltd. | MEDICINES COMPRISING Rho KINASE INHIBITOR |
WO2001091754A1 (en) * | 2000-05-30 | 2001-12-06 | Peptor Ltd. | Protein kinase inhibitors |
US20030180830A1 (en) * | 2002-02-14 | 2003-09-25 | Pyro Pharmaceuticals, Inc. | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway |
WO2004087943A1 (en) * | 2003-03-29 | 2004-10-14 | Astrazeneca Ab | Method |
US20050164323A1 (en) * | 2003-12-24 | 2005-07-28 | Wyeth | Methods of treating asthma |
Non-Patent Citations (9)
Title |
---|
KUIJL COENRAAD ET AL: "Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1", NATURE (LONDON), vol. 450, no. 7170, November 2007 (2007-11-01), pages 725, XP002489301, ISSN: 0028-0836 * |
KUSNER D J: "Mechanisms of mycobacterial persistence in tuberculosis", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 114, no. 3, 1 March 2005 (2005-03-01), pages 239 - 247, XP004753479, ISSN: 1521-6616 * |
LE STUNFF HERVE ET AL: "The roles of protein kinase C and tyrosine kinases in mediating endothelin-1-stimulated phospholipase D activity in rat myometrium: Differential inhibition by ceramides and cyclic AMP", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 292, no. 2, February 2000 (2000-02-01), pages 629 - 637, XP002489300, ISSN: 0022-3565 * |
MALIK Z A ET AL: "Mycobacterium tuberculosis phagosomes exhibit altered calmodulin-dependent signal transduction: contribution to inhibition of phagosome-lysosome fusion and intracellular survival in human macrophages.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 MAR 2001, vol. 166, no. 5, 1 March 2001 (2001-03-01), pages 3392 - 3401, XP002502829, ISSN: 0022-1767 * |
MARIA-PILAR J D B ET AL: "Cellular bioterrorism: how Brucella corrupts macrophage physiology to promote invasion and proliferation", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 114, no. 3, 1 March 2005 (2005-03-01), pages 227 - 238, XP004753478, ISSN: 1521-6616 * |
NAKAMURA S ET AL: "EFFECTS OF ISOQUINOLINESULPHONAMIDE COMPOUNDS ON MULTIDRUG-RESISTANT P388 CELLS", JOURNAL OF PHARMACY AND PHARMACOLOGY, LONDON, vol. 45, no. 4, 1 January 1993 (1993-01-01), pages 268 - 273, XP009011437, ISSN: 0022-3573 * |
PENN R B ET AL: "Pharmacological Inhibition of Protein Kinases in Intact Cells: Antagonism of Beta Adrenergic Receptor Ligand Binding by H-89 Reveals Limitations of Usefulness", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, EXPERIMENTAL THERAPEUTICS, BALTIMORE, MD, vol. 288, no. 2, 1 January 1999 (1999-01-01), pages 428 - 437, XP002405317, ISSN: 0022-3565 * |
UCHIYA KEI-ICHI ET AL: "Involvement of Salmonella pathogenicity island 2 in the up-regulation of interleukin-10 expression in macrophages: Role of protein kinase a signal pathway", INFECTION AND IMMUNITY, vol. 72, no. 4, April 2004 (2004-04-01), pages 1964 - 1973, XP002489299, ISSN: 0019-9567 * |
ZEIGERER ANJA ET AL: "Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160.", MOLECULAR BIOLOGY OF THE CELL OCT 2004, vol. 15, no. 10, October 2004 (2004-10-01), pages 4406 - 4415, XP002502830, ISSN: 1059-1524 * |
Also Published As
Publication number | Publication date |
---|---|
GB0617222D0 (en) | 2006-10-11 |
WO2008026075A2 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008098104A8 (en) | Inhibitors of akt activity | |
EP3947368A4 (en) | Cdk2/5 degraders and uses thereof | |
IL183249A0 (en) | Packaging articles, films and methods that promote or preserve the desirable color of meat | |
EP1835929B8 (en) | Anti-kir combination treatments and methods | |
EP2497470B8 (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors | |
WO2011046964A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2007126883A3 (en) | Surveying sterilizer methods and systems | |
WO2007076423A3 (en) | INHIBITORS OF Akt ACTIVITY | |
WO2008060795A3 (en) | Antimicrobial articles and method of manufacture | |
WO2008121742A3 (en) | Inhibitors of bruton's tyrosine kinase | |
EP2344738A4 (en) | Methods and systems for controlling the products of combustion | |
HK1139036A1 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
ZA200707929B (en) | Azole derivatives in the form of lipase and phospholipase inhibitors | |
WO2008030836A3 (en) | Bcl inhibitors treating platelet excess | |
WO2007025169A3 (en) | Hif inhibitors | |
WO2007017267A3 (en) | Novel compounds | |
PL2231636T3 (en) | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases | |
WO2005079300A9 (en) | Protein kinase inhibitors and methods for identifying same | |
WO2007050795A3 (en) | Transglutaminase inhibitors and methods of use thereof | |
EP2030615A3 (en) | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | |
WO2006081182A3 (en) | Antibacterial agents | |
EP1922086A4 (en) | Targeted protein kinase c inhibitors and uses thereof | |
WO2007059226A3 (en) | Photoactivatable antimicrobial agents | |
WO2009158374A3 (en) | Inhibitors of akt activity | |
WO2006081178A3 (en) | Antibacterial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07825702 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07825702 Country of ref document: EP Kind code of ref document: A2 |